A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations

NCT ID: NCT03793140

Last Updated: 2025-04-16

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-12-31
• Study Completion Date: 2025-12-31

Brief Summary

The purpose of this study is to test any good and bad effects of the study drug, CPI-613.

Conditions

Lymphoma; Leukemia

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

CPI-613

CPI-613 IV induction (Days 1-5 for first 2 Cycles \[14-day cycles\]), followed by CPI-613 IV maintenance (Days 1-5 for all Cycles thereafter \[21-day cycles\].

Group Type: EXPERIMENTAL

CPI-613

Intervention Type: DRUG

CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) Induction tx: Cycle 1 and 2: Treatment on Days 1-5 (Each cycle is 14 days). (Each Cycle is 14 days) Maintenance tx: All subsequent Cycles: Treatment with CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) on Days 1-5 (Each Cycle is 21 days)

Interventions

CPI-613

CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) Induction tx: Cycle 1 and 2: Treatment on Days 1-5 (Each cycle is 14 days). (Each Cycle is 14 days) Maintenance tx: All subsequent Cycles: Treatment with CPI-613 \[2,500 mg/m2/day IV\] over 2 hours (+/- 10 mins) on Days 1-5 (Each Cycle is 21 days)

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Must be ≥ 12 years of age.
• Histologic diagnosis of Burkitt Lymphoma/Leukemia or high-grade B-cell lymphoma with rearrangements of MYC and BCL2 and/or BCL6 confirmed at enrolling institution or plasmablastic lymphoma or high-grade B-cell lymphoma with rearrangements of MYC without bcl-2
• Failure of at least one previous line of therapy.
• Failure after prior bone marrow transplant, or ineligible for or opted not to participate in bone marrow transplantation for Burkitt Lymphoma/Leukemia, or DHL/THL.
• ECOG Performance Status of ≤ 3.

1. For patients less than 16 years of age, Lansky score ≥ 30

2. For patients 16- 17 years of age, Karnofsky score ≥ 30

• Measurable disease as defined RECIL criteria (2017) or isolated bone marrow involvement.
• Patients must have fully recovered from the acute, non-hematological, non-infectious toxicities of any prior treatment with anti-cancer drugs, radiotherapy or other anti-cancer modalities. Patients with persistent, non-hematologic, non-infectious toxicities from prior treatment must have documented resolution to ≤ Grade 2.
• Patients must have, or be willing and eligible to undergo placement of, a working central venous access device
• Venous access available (e.g., portacath, PICC line or equivalent).
• Laboratory values obtained ≤ 2 weeks prior to enrollment must demonstrate adequate hepatic function, renal function, and coagulation as defined below:

• Aspartate aminotransferase (AST/SGOT) ≤ 5x upper normal limit (ULN)
• Alanine aminotransferase (ALT/SGPT) ≤ 5x ULN
• Total bilirubin ≤1.5x ULN (unless related to hemolysis or Gilbert's syndrome, or involvement by lymphoma; if involvement by lymphoma: total bilirubin </= 3.0 x ULN)
• Creatinine clearance >=40cc min either by 24-hour creatinine clearance or calculated from the modified Cockcroft-Gault equation (with the use of ideal body mass [IBM] instead of mass): CRCL =(140-Age) × IBM (kg) × [0.85 if female]/[(72 • serum creatinine (mg/dL)]
• For patients less than 16 years of age, the Bedside Schwartz equation or Creatinine-Cystatin C-based CKiD equation should be used for creatinine-based GFR calculation
• International Normalized Ratio (INR) must be <1.5. Due to the occurrence of thrombocytopenia, patients should not enter with coagulopathy. Patients on anticoagulants should be on short-acting therapy (e.g. low molecular weight heparin) rather than oral anticoagulants.
• Albumin ≥2.0 g/dL (or ≥20 g/L)
• Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must use accepted contraceptive methods (abstinence, intrauterine device [IUD], oral contraceptive or double barrier device) during the study and must have a negative serum or urine pregnancy test within 2 weeks prior to treatment initiation.
• Females must agree to abstain from breastfeeding during study participation
• Fertile men must practice effective contraceptive methods during the study unless documentation of infertility exists.

Exclusion Criteria

• Patients that have received a chemotherapy regimen with stem cell support in the previous 2 months.
• Any medical condition that is clinically unstable despite present therapy (i.e. uncontrolled infection).
• Platelets < 50,000/mm3 unless attributable to marrow based (either Burkitt lymphoma or DHL/THL.) Note: Patients with leukemia/lymphoma in the marrow 25,000-50,000 will be assessed for grade 4 thrombocytopenia unless they have platelet recovery above grade 3. Patients entering with platelets <25,000 will only be assessed for thrombocytopenia related to drug if they recover to grade 3 or higher.
• Serious medical illness, such as significant cardiac disease (e.g. symptomatic congestive heart failure, unstable angina pectoris, coronary artery disease, myocardial infarction within the past 3 months, uncontrolled cardiac arrhythmia, pericardial disease or New York Heart Association Class III or IV), or severe debilitating pulmonary disease, that would potentially increase patient's risk for toxicity.
• Patients with active central nervous system (CNS) parenchymal disease. Patients with leptomeningeal disease are allowed as long as the CSF has cleared for more than 4 weeks and the patient is receiving maintenance intrathecal/intra Ommaya therapy.
• Any active uncontrolled bleeding or bleeding diathesis (e.g., active peptic ulcer disease).
• Any condition or abnormality which may, in the opinion of the investigator, compromise his or her safety.
• HIV patients with any of the following: a) uncontrolled HIV infection defined as an HIV viral load > 100K copies/mL, b) a documented opportunistic infection within the last 90 days, c) concurrent HIV therapy with zidovudine or any strong CYP3A4 inhibitor (e.g. ritonavir or cobicistat) within 7 days of study drug due to potential drug-drug interaction.
• Patients who have received radiotherapy, surgery, treatment with cytotoxic agents, treatment with biologic agents, immunotherapy , or any other anti-cancer therapy for any kind for cancer, or any other investigational agent for any indication, within the past 2 weeks prior to initiation of CPI-613 treatment with the exclusion of radiation to one area (e.g. whole brain or involved nodal site) that does not interfere with response assessment in other sites. A course of steroids (up to 14 days total) prior to study initiation is acceptable.
• Psychiatric illness or social situation that would limit the patient's ability to tolerate and/or comply with study requirements.
• Prior allogeneic stem cell transplant within 2 months of study start

1. Patients with active graft-versus-host-disease are not eligible

2. Patients receiving immunosuppressive therapy for prevention of graft-versus-host disease are not eligible

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

City of Hope Medical Center

OTHER

Sponsor Role: collaborator

Massachusetts General Hospital

OTHER

Sponsor Role: collaborator

M.D. Anderson Cancer Center

OTHER

Sponsor Role: collaborator

George Washington University

OTHER

Sponsor Role: collaborator

Memorial Sloan Kettering Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Ariela Noy, MD

Role: PRINCIPAL_INVESTIGATOR

Memorial Sloan Kettering Cancer Center

Locations

City of Hope

Duarte, California, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Memorial Sloan Kettering Basking Ridge

Basking Ridge, New Jersey, United States

Memorial Sloan Kettering Monmouth

Middletown, New Jersey, United States

Memorial Sloan Kettering Bergen

Montvale, New Jersey, United States

Memorial Sloan Kettering Commack

Commack, New York, United States

Memorial Sloan Kettering Westchester

Harrison, New York, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

Memorial Sloan Kettering Nassau

Uniondale, New York, United States

University of Pennsylvania (Data Collection Only)

Philadelphia, Pennsylvania, United States

Md Anderson Cancer Center

Houston, Texas, United States

Countries

United States

References

Steiner RE, Nikolaenko L, Nair R, Seshan VE, Thiruvengadam S, Khan N, Abramson JS, Horwitz SM, Matasar MJ, Owens CN, Rodriguez-Rivera II, Strauss D, Pardee TS, Luther S, Saboukoulou S, Thet WS, Vemuri S, Noy A. Novel Devimistat Results in Complete Remissions in Heavily Pre-Treated Burkitt Lymphoma in a phase II trial. Blood Adv. 2025 Jul 17:bloodadvances.2025016168. doi: 10.1182/bloodadvances.2025016168. Online ahead of print.

Reference Type: DERIVED

PMID: 40674734 (View on PubMed)

Related Links

http://www.mskcc.org/mskcc/html/44.cfm

Memorial Sloan Kettering Cancer Center

Other Identifiers

18-443

Identifier Type: -

Identifier Source: org_study_id